$52.8 M

CLRB Mkt cap, 12-Nov-2021
Cellectar Biosciences Net income (Q1, 2021)-6.4 M
Cellectar Biosciences EBIT (Q1, 2021)-6.4 M
Cellectar Biosciences Cash, 31-Mar-202153.6 M
Cellectar Biosciences EV-417.8 K
Get notified regarding key financial metrics and revenue changes at Cellectar BiosciencesLearn more
Banner background

Cellectar Biosciences Income Statement

Cellectar Biosciences Balance Sheet

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

3.3m1.6m3.8m7.1m5.6m7.9m5.8m5.1m3.8m1.6m11.6m7.0m4.8m2.5m1.9m7.9m5.6m11.2m8.3m5.7m6.8m4.2m16.4m10.5m16.8m13.3m7.1m22.5m53.6m

Prepaid Expenses

53.1k303.6k183.3k139.0k336.0k191.8k147.4k329.4k212.3k335.0k290.4k171.0k118.6k445.3k281.4k162.2k437.6k893.2k969.6k970.2k770.0k780.6k686.0k604.7k1.3m1.5m771.3k593.6k774.9k

Current Assets

3.5m2.1m4.0m7.3m6.0m8.1m6.0m5.5m4.1m2.0m11.9m7.3m5.0m3.0m2.2m8.1m6.1m12.2m9.3m6.7m7.6m5.0m17.1m11.1m18.2m14.8m7.9m23.0m54.4m

PP&E

3.2m3.2m2.9m2.8m2.7m2.6m2.5m2.4m2.3m2.2m2.1m2.0m1.9m1.8m1.6m1.6m1.5m1.4m1.6m1.5m228.8k212.0k192.0k516.8k492.7k461.9k411.7k410.6k317.9k

Goodwill

1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m

Total Assets

8.4m7.0m8.6m11.9m10.4m14.3m12.1m9.6m8.0m5.9m15.7m10.9m8.6m6.5m5.6m11.4m9.3m15.3m12.6m9.9m9.6m7.0m19.5m12.5m19.1m15.7m8.7m23.9m55.1m

Accounts Payable

365.8k441.7k471.6k607.9k712.8k863.0k1.0m1.2m992.3k1.2m1.1m824.2k712.2k579.8k608.7k816.8k1.1m1.2m1.5m2.0m1.9m2.1m2.6m2.1m2.5m2.9m2.9m3.2m4.9m

Short-term debt

2.2k2.2k2.3k2.3k2.4k2.4k2.5k2.3k1.1k41.8k105.4k182.6k243.1k244.8k247.3k211.5k150.6k2.8k2.9k2.9k3.1k3.2k3.0k1.4k568.0109.3k112.7k123.6k

Current Liabilities

449.5k521.8k506.3k635.7k736.8k6.6m6.1m4.6m4.4m4.1m2.1m5.9m5.8m5.5m2.8m1.4m1.4m1.4m1.6m2.1m2.1m2.3m2.7m2.2m2.7m3.0m3.1m3.3m5.0m

Long-term debt

5.2k4.7k3.5k2.9k2.3k1.1k431.0450.0k4.2m4.2m357.9k279.5k218.2k156.5k32.2k6.6k6.0k4.5k3.8k3.3k1.4k568.0502.2k476.2k449.6k393.0k547.5k269.3k

Non-Current Liabilities

573.7k576.1k580.9k583.3k585.5k588.7k590.2k591.9k4.4m4.4m505.1k427.8k367.0k305.8k180.8k154.9k153.8k149.9k147.9k146.0k1.4k568.0502.2k476.2k449.6k393.0k547.5k

Total Debt

7.4k6.9k5.8k5.2k4.7k3.5k2.9k900.0k900.0k41.3k103.3k462.1k240.8k242.4k244.8k208.9k147.9k6.6k6.2k4.5k3.8k3.0k503.6k476.8k449.6k502.2k660.2k393.0k

Total Liabilities

1.1m1.2m1.3m7.2m6.7m5.2m8.8m8.4m2.6m6.3m6.2m5.8m3.0m1.5m1.6m1.5m1.7m2.3m2.1m2.3m2.7m2.7m3.2m3.4m3.4m3.9m5.3m

Common Stock

268.0268.0369.0431.0434.0574.0574.0574.0574.029.076.076.076.076.09.054.054.0135.0135.0135.0171.017.043.051.094.094.094.0254.0527.0

Preferred Stock

637.0k1.1m

Additional Paid-in Capital

35.0m35.4m41.4m46.7m47.2m50.9m51.2m51.5m53.3m53.5m69.7m66.0m66.1m66.2m66.4m75.7m75.9m87.4m87.7m87.9m94.6m95.5m107.1m109.3m119.2m119.4m119.7m138.1m171.2m

Retained Earnings

(56.1m)(56.6m)(61.4m)(63.7m)(65.6m)(63.8m)(65.9m)(68.2m)(73.7m)(76.8m)(80.3m)(87.8m)(90.7m)(93.8m)(101.2m)(104.4m)(108.3m)(115.6m)(119.3m)(133.1m)

Total Equity

7.4m5.9m7.6m10.6m9.1m7.1m5.4m4.4m(727.3k)(2.5m)13.1m4.6m2.4m680.2k2.6m9.8m7.7m13.7m10.9m7.6m7.5m4.7m16.9m9.8m16.0m12.2m5.2m20.0m49.8m

Debt to Equity Ratio

0 x0 x0 x0 x0 x0 x0 x0.2 x-1.2 x0 x0 x0.1 x0.1 x0.4 x0.1 x0 x0 x0 x0 x0 x0 x0 x0.1 x0 x

Debt to Assets Ratio

0 x0 x0 x0 x0 x0 x0 x0.1 x0.1 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x

Financial Leverage

1.1 x1.2 x1.1 x1.1 x1.1 x2 x2.2 x2.2 x-11.1 x-2.3 x1.2 x2.4 x3.6 x9.5 x2.2 x1.2 x1.2 x1.1 x1.2 x1.3 x1.3 x1.5 x1.2 x1.3 x1.2 x1.3 x1.7 x1.2 x1.1 x

Cellectar Biosciences Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Net Income

(3.6m)(5.5m)(2.4m)(4.6m)(6.6m)(3.5m)(5.5m)(6.8m)(2.9m)(5.0m)(5.5m)(2.3m)(4.6m)(6.4m)824.6k(1.3m)(3.6m)(2.9m)(6.0m)(9.5m)(3.5m)(6.4m)(9.4m)(3.6m)(6.8m)(10.7m)(4.0m)(7.6m)(6.4m)

Depreciation and Amortization

290.7k439.6k139.8k266.1k384.1k111.9k220.0k325.7k96.0k188.4k277.7k90.0k180.7k271.5k90.8k181.5k269.3k86.9k188.3k294.2k17.3k34.2k50.1k32.7k66.3k100.2k33.9k69.6k35.1k

Accounts Payable

(407.2k)(331.4k)(6.4k)129.8k234.8k146.0k304.5k440.3k(169.8k)33.3k(22.6k)(109.7k)(221.8k)(354.1k)(67.3k)140.8k411.5k(230.3k)49.9k602.8k16.0k225.9k703.8k511.3k984.2k1.3m277.5k543.2k1.5m

Cash From Operating Activities

(2.9m)(4.4m)(1.7m)(3.2m)(4.9m)(1.9m)(3.9m)(6.5m)(2.6m)(4.6m)(6.7m)(2.4m)(4.6m)(6.7m)(1.8m)(3.7m)(5.9m)(3.0m)(5.7m)(8.2m)(3.2m)(5.7m)(8.7m)(2.8m)(5.5m)(9.0m)(3.5m)(6.6m)(4.8m)

Purchases of PP&E

(23.1k)(112.2k)(15.1k)(29.1k)(37.1k)(93.0k)(93.0k)(135.0k)(15.2k)(15.2k)(17.4k)(25.5k)(33.7k)(39.8k)(4.2k)(5.3k)(66.3k)(320.5k)(346.7k)(1.4k)(1.4k)(1.4k)(6.2k)(15.7k)(18.8k)(10.6k)(45.1k)

Cash From Investing Activities

1.4m1.3m(15.1k)(29.1k)(37.1k)28.8k28.8k1.9m(15.2k)(15.2k)(17.4k)(25.5k)(33.7k)(39.8k)(4.2k)(5.3k)(66.3k)(320.5k)(346.7k)(1.4k)(1.4k)43.6k(6.2k)(15.7k)(18.8k)(10.6k)(45.1k)

Short-term Borrowings

(617.5k)(86.6k)(86.6k)(86.6k)

Long-term Borrowings

(675.7k)(675.7k)(544.0)(1.8k)(626.0)(1.3k)(1.7k)(1.2k)(2.1k)(62.0k)(61.1k)(122.5k)(184.1k)(655.0)(1.3k)(1.8k)(728.0)(1.5k)(2.2k)(811.0)(1.6k)(2.2k)

Cash From Financing Activities

4.2m4.1m(544.0)4.9m5.0m5.0m5.0m5.0m4.0m3.8m15.9m(1.2k)(2.1k)(191.7k)(131.2k)7.8m7.7m2.8m2.8m2.8m(728.0)(94.6k)15.0m(811.0)9.0m9.0m18.4m1.2m

Net Change in Cash

2.6m917.0k(1.7m)1.6m91.8k3.2m1.2m432.9k1.4m(792.4k)9.2m(2.4m)(4.6m)(7.0m)(1.9m)4.1m1.8m(206.2k)(3.1m)(5.8m)(3.2m)(5.8m)6.4m(2.8m)3.5m(9.0k)(3.5m)11.8m(3.5m)

Interest Paid

13.7k13.7k22.6k43.6k1.5k2.8k3.7k364.0364.0364.0880.0880.01.9k1.6k1.6k

Cellectar Biosciences Ratios

USDQ2, 2011

Financial Leverage

1.1 x